All companies
Visit website
Venomyx Therapeutics
OperatingVenomyx, Inc
EpiPen for snakebites: the antivenom of tomorrow!
Valuation cap ⓘ
$5.0M
As of Mar 2019 · from Reg CF Offering (2018) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$269,844
Across 1 round since 2018
Latest share price
$1.00
Reg CF Offering (2018) offering price
Financials
FY2016–FY2017 · from SEC filings · hover any figure for its source$0
−$116K
2016
$0
−$158K
2017
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016
FY2017
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$116,136
-$158,248
Taxes paid
$0
$0
Balance sheet
Cash
$95,158
$10,226
Accounts receivable
$0
$0
Total assets
$115,158
$155,226
Short-term debt
$0
$0
Long-term debt
$100,000
$202,500
Total liabilities
$100,000
$202,500
Other
Headcount
—
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$5.0M
Valuation cap
Reg CF Offering (2018)
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $269.8K / $107KInvestors 473Valuation cap $5M
Reg CF annual-report compliance
Delinquent
Filed 0 of 8 annual reports (FY2018–FY2025)
Missing: 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025
473 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001755717Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.